Evidence map›Paper›PMID 35932388›Full record

ArticleInvestigational new drugs2022

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.

Xiaofei Zhou, Ulka Vaishampayan, Devalingam Mahalingam, R Donald Harvey, Ki Young Chung, Farhad Sedarati, Cassie Dong, Douglas V Faller, Karthik Venkatakrishnan, Neeraj Gupta

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigational new drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03486314 (A Phase 1 Study to Evaluate the Effects of Rifampin on Pharmacokinetics of Pevonedistat in Patients With Advanced Solid Tumors), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03486314 phase1completednot on this map

A Phase 1 Study to Evaluate the Effects of Rifampin on Pharmacokinetics of Pevonedistat in Patients With Advanced Solid Tumors

TypeinterventionalSponsorMillennium Pharmaceuticals, Inc.Ran2018 to 2021Enrolled20ConditionsAdvanced Solid NeoplasmArmsPevonedistat, Rifampin, Docetaxel, Carboplatin, Paclitaxel
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Xiaofei ZhouTakeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA. xiaofei.zhou@takeda.com.
Ulka VaishampayanKarmanos Cancer Institute, Detroit, MI, USA.
Devalingam MahalingamNorthwestern Medical Group, Chicago, IL, USA.
R Donald HarveyEmory University, Atlanta, GA, USA.
Ki Young ChungPrisma Health Cancer Institute/ITOR, Greenville, SC, USA.
Farhad SedaratiTakeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Cassie DongTakeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Douglas V FallerTakeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Karthik VenkatakrishnanTakeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Neeraj GuptaTakeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Takeda (United States) · USEmory University · USNorthwestern Medicine · USOno Pharmaceutical (United States) · USPrisma Health · USUniversity of Michigan–Ann Arbor · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pevonedistat (TAK-924/MLN4924) is an investigational small molecule inhibitor of the NEDD8-activating enzyme that has demonstrated clinical activity across solid tumors and hematological malignancies. Here we report the results of a phase 1 study evaluating the effect of rifampin, a strong CYP3A inducer, on the pharmacokinetics (PK) of pevonedistat in patients with advanced solid tumors (NCT03486314). Patients received a single 50 mg/m

Indexed as

NeoplasmsRifampinArea Under CurveCyclopentanesDrug InteractionsEnzyme InhibitorsHumansNEDD8 ProteinPyrimidinesCyclopentanesEnzyme InhibitorsNEDD8 ProteinNEDD8 protein, humanpevonedistatPyrimidinesRifampinAdvanced malignanciesPevonedistatPharmacokinetics [4 to 6 max]Rifampin

Identifiers

PMID35932388
PMCPMC9395450
OpenAlexW4289978797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.